Brokerages expect DURECT Co. (NASDAQ:DRRX) to report ($0.05) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for DURECT’s earnings. The lowest EPS estimate is ($0.05) and the highest is ($0.04). DURECT also reported earnings of ($0.05) per share in the same quarter last year. The firm is scheduled to report its next quarterly earnings report on Monday, May 10th.
According to Zacks, analysts expect that DURECT will report full-year earnings of ($0.18) per share for the current financial year, with EPS estimates ranging from ($0.21) to ($0.16). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.48) to ($0.07). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover DURECT.
DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Wednesday, March 3rd. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). DURECT had a negative net margin of 21.85% and a negative return on equity of 33.98%. The business had revenue of $2.21 million during the quarter, compared to the consensus estimate of $6.67 million.
A number of equities analysts have issued reports on DRRX shares. Zacks Investment Research raised shares of DURECT from a “sell” rating to a “hold” rating in a research note on Tuesday, March 9th. Chardan Capital raised their price objective on shares of DURECT from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, February 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $5.83.
Institutional investors and hedge funds have recently bought and sold shares of the business. Zacks Investment Management acquired a new stake in DURECT in the fourth quarter worth $36,000. Virtu Financial LLC acquired a new stake in shares of DURECT during the fourth quarter worth $36,000. Teacher Retirement System of Texas raised its holdings in shares of DURECT by 59.7% during the fourth quarter. Teacher Retirement System of Texas now owns 18,068 shares of the specialty pharmaceutical company’s stock worth $37,000 after acquiring an additional 6,754 shares during the period. Federated Hermes Inc. acquired a new stake in shares of DURECT during the third quarter worth $31,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of DURECT during the fourth quarter worth $38,000. Institutional investors own 53.83% of the company’s stock.
DRRX stock traded up $0.01 during midday trading on Friday, reaching $1.82. The company’s stock had a trading volume of 9,071 shares, compared to its average volume of 2,214,078. DURECT has a 52 week low of $1.46 and a 52 week high of $2.96. The stock has a market cap of $413.51 million, a PE ratio of -36.19 and a beta of 1.76. The company has a quick ratio of 5.57, a current ratio of 5.95 and a debt-to-equity ratio of 0.60. The business’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $2.05.
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Article: Why does the United States have a lingering trade deficit?
Get a free copy of the Zacks research report on DURECT (DRRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.